[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-year tamoxifen treatment - a case report].
We report an 89-year-old patient with recurrent hormone-responsive breast cancer who presented with pleural, skin and bone metastases. Nineteen years previously, she had undergone a mastectomy and then for 16 years received adjuvant hormone therapy. The patient was orally administered a combination therapy of anastrozole, UFT and cyclophosphamide. A remarkable response was seen after 5 months, and no side effects were observed. The patient became well and the treatment was continued without relapse at 8 months. Oral anti-cancer treatments in combination with hormone therapy appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients.
Sakurai
Teruhisa
T
Dept. of Surgery, Wakayama Medical University Kihoku Hospital.
Umemura
Teiji
T
Jinta
Eri
E
Suzuma
Takaomi
T
Yoshimura
Goro
G
Shimizu
Sayuri
S
Sakurai
Takeo
T
D000369:Aged, 80 and over; D000077384:Anastrozole; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use*; D010997:Pleural Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D011859:Radiography; D012008:Recurrence; D012878:Skin Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D013629:Tamoxifen / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use; D013997:Time Factors; D014230:Triazoles / Q000627:therapeutic use*; D014498:Uracil / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D005641:Tegafur; D000077384:Anastrozole; D014498:Uracil; D003520:Cyclophosphamide